Zarmeena Vendal

2 months ago | healio.com | Anthony DeFino |Zarmeena Vendal |Christine Klimanskis

In this Healio Video Perspective, Zarmeena Vendal, MD, discusses her positive experience with the Voyager direct selective laser trabeculoplasty device and its contribution to interventional glaucoma. According to Vendal, Voyager (Alcon) can help increase access to care for patients with glaucoma and offers “efficiency and ease” of use for her practice staff. In addition, patients’ reactions have been positive, Vendal said.

Oct 31, 2024 | glaucomaphysician.net | Zarmeena Vendal

Traditionally, the surgical space for cataract surgery has been very limited for primary open-angle glaucoma (POAG) patients. Fortunately, today we are on the forefront of innovation when it comes to finding a solution for these patients, because there are multiple lens implant choices that can help us push limits and provide satisfying visual outcomes.

Aug 24, 2024 | glaucomatoday.com | Christine Larsen |Zarmeena Vendal |Lorraine M. Provencher |Arsham Sheybani

A few years into practice, I felt like I was having the same conversation with every new glaucoma patient I saw in my office. The first part of the visit involved a series of questions. “When were you first diagnosed with glaucoma?” “What drops have you used?” “Any family history?” I used these inquiries to piece together a history of the patient’s disease with the goal of determining an initial target pressure and a corresponding treatment plan.

Apr 5, 2024 | healio.com | Zarmeena Vendal |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than half of all patients treated with glaucoma medications have ocular surface disease, which predominantly manifests as dry eye disease.

Mar 20, 2024 | theophthalmologist.com | Zarmeena Vendal

Why amniotic membrane therapy is an increasingly popular option for treating ocular surface diseaseZarmeena Vendal | | 5 min read | Discussion Because of its regenerative properties, ophthalmologists are increasingly using amniotic membrane therapy to treat ocular surface disease (OSD) (1-4). The most common forms of OSD are blepharitis and dry eye disease (DED), which may be related to meibomian gland dysfunction (MGD) and reduced tear production, among other factors (5).